Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Some orthopaedic surgeons believe that relatively 'young' older patients (aged ≤ 75 years) who have sustained a femoral neck fracture should be treated with hemiarthroplasty (HA) instead of total hip arthroplasty (THA). The rationale behind this belief is that THA is more time consuming, has greater associated surgical morbidity and may increase the risk of hip dislocation and subsequent revision surgery. On the other hand, HA is believed to accelerate acetabular erosion (i.e. wear) over time, which may ultimately lead to the need for conversion surgery from HA to THA. Due to a lack of rese...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • having had a displaced femoral neck fracture that was subsequently treated with hemiarthroplasty
- • aged \< 75 years at the time of surgery
- • have at least two post-operative radiographs (with at least six weeks between them) available for acetabular erosion measurements.
- Exclusion Criteria:
- • patients diagnosed with rheumatoid arthritis, osteoporosis, hip dysplasia or a previous hip fracture of the ipsilateral hip.
About Rijnstate Hospital
Rijnstate Hospital is a leading healthcare institution based in the Netherlands, dedicated to providing high-quality patient care and advancing medical research. With a strong emphasis on innovation and collaboration, Rijnstate Hospital actively engages in clinical trials to explore new treatment options and improve patient outcomes across various medical fields. The hospital's multidisciplinary approach integrates the expertise of healthcare professionals, researchers, and academic partners, ensuring rigorous scientific methodologies and adherence to ethical standards. Committed to enhancing the health and well-being of the communities it serves, Rijnstate Hospital plays a pivotal role in the advancement of medical knowledge and the development of effective therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Arnhem, Gelderland, Netherlands
'S Hertogenbosch, , Netherlands
Alkmaar, , Netherlands
Eindhoven, , Netherlands
Zwolle, , Netherlands
Patients applied
Trial Officials
Matthijs P. Somford, MD, PhD
Principal Investigator
Stichting Rijnstate Ziekenhuis
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported